Results

Total Results: over 10,000 records

Showing results for "consideration".

9521. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/LPaUxRbrTshfsYVVTzenEQ
      April 26, 2022 - the net benefit, see the USPSTF Procedure Manual.3 Practice Considerations Patient Population Under Consideration

9522. Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/_2-KL_eHkuBhbGrzcAHsB-
      June 01, 2022 - net ben- efit, see the USPSTF Procedure Manual.4 Practice Considerations Patient Population Under Consideration

9523. JAMA JATS (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/UA7cEG8wH4xh8-fr7Lfw9q
      September 18, 2018 - Clinical Considerations Patient Population Under Consideration This recommendation applies to adults

9524. Archived: Risk Factors and Other Epidemiologic Considerations for Cervical Cancer Screening: A Narrative Review for the U.S. Preventive Services Task Force: Cervical Cancer: Screening | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/risk-factors-and-other-epidemiologic-considerations-for-cervical-cancer-screening-a-narrative-review-for-the-us-preventive-services-task-force/cervical-cancer-screening-2012
      October 15, 2011 - Persistence of HPV An important consideration

9525. Archived: Final Evidence Summary: Folic Acid to Prevent Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary25/folic-acid-to-prevent-neural-tube-defects-preventive-medication
      May 15, 2009 - The USPSTF developed 2 key questions (KQs) from the analytic framework to guide its consideration of … concealment and whether potential confounders were distributed equally among groups For cohort studies: Consideration … of potential confounders with either restriction or measurement for adjustment in the analysis; consideration

9526. Making Healthcare Safer III: Executive Summary | Agency for Healthcare Research and Quality
      ce.effectivehealthcare.ahrq.gov/research/findings/making-healthcare-safer/mhs3/exe-summary.html
      March 01, 2020 - factors to delirium in a variety of care settings, and strategies to appropriately manage delirium Consideration … When using a specific PSP, consideration must be given to potential new harms that can be introduced. … It is extremely difficult, and sometimes may be impossible, to design a study that takes into consideration

9527. Disposition of Comments for CER 168 Infantile Hemangioma (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/infantile-hemangioma_disposition-comments.pdf
      January 15, 2016 - clinicians and families may take factors such as lesion location, type, size, and patient values into consideration … TEP reviewer #4 General ES 17 I understand the issues with US BUT Age is a big consideration for … clinicians and families may take factors such as lesion location, type, size, and patient values into consideration

9528. GRADING THE STRENGTH OF A BODY OF EVIDENCE (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-grading-strength_methods.pdf
      July 01, 2009 - a single, direct link between the interventions of interest and the ultimate health outcome under consideration … grade will be determined by a point system for combining ratings of the domains or by a qualitative consideration … : • Study design (e.g., RCTs or observational studies) • Aggregate quality of the studies under consideration

9529. DEcIDE 32: The Incident User Design in Comparative Effectiveness Research (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/incident-user-design_research.pdf
      May 01, 2012 - Variables ..................................................................................8 Adequate Consideration … comprehensive account of its value in reducing bias.4 McMahon and MacDonald provide an earlier and thoughtful consideration … Adequate Consideration of Time Since Marketing and Time Since Initiation Incident user designs add

9530. Disposition of Comments for CER 168 Infantile Hemangioma (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/infantile-hemangioma_disposition-comments.pdf
      January 15, 2016 - clinicians and families may take factors such as lesion location, type, size, and patient values into consideration … TEP reviewer #4 General ES 17 I understand the issues with US BUT Age is a big consideration for … clinicians and families may take factors such as lesion location, type, size, and patient values into consideration

9531. Grading the Strength of a Body of Evidence when Comparing Medical Interventions | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/methods-guidance-grading-strength/methods
      December 01, 2019 - reflects a single, direct link between the interventions of interest and the ultimate health outcome under consideration … grade will be determined by a point system for combining ratings of the domains or by a qualitative consideration … : Study design (e.g., RCTs or observational studies) Aggregate quality of the studies under consideration

9532. DEcIDE 32: The Incident User Design in Comparative Effectiveness Research (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/incident-user-design_research.pdf
      May 01, 2012 - Variables ..................................................................................8 Adequate Consideration … comprehensive account of its value in reducing bias.4 McMahon and MacDonald provide an earlier and thoughtful consideration … Adequate Consideration of Time Since Marketing and Time Since Initiation Incident user designs add

9533. GRADING THE STRENGTH OF A BODY OF EVIDENCE (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-grading-strength_methods.pdf
      July 01, 2009 - a single, direct link between the interventions of interest and the ultimate health outcome under consideration … grade will be determined by a point system for combining ratings of the domains or by a qualitative consideration … : • Study design (e.g., RCTs or observational studies) • Aggregate quality of the studies under consideration

9534. Archived: Evidence Summary: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication, 2002 | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/aspirin-use-prevent-cardiovascular-disease-colorectal-cancer-preventive-medication-2002
      January 15, 2002 - The decision about whether to use aspirin chemoprevention requires consideration of the patient's cardiovascular … The advantage of such an approach is that it allows a more specific and accurate discussion and consideration … Consideration of underlying CHD risk, as well as the relative values patients attach to the main outcomes

9535. Health IT-Supported Process for Preventing and Managing Venous Thromboembolism (VTE) - Final Report (pdf file)
      digital.ahrq.gov/sites/default/files/docs/citation/r01hs022086-carayon-final-report-2019.pdf
      January 01, 2019 - include restriction of these studies to high-risk patients, focus on prophylaxis with little or no consideration … for VTE diagnosis and treatment, and lack of consideration for sociotechnical system factors in CDS … Educational support (e.g., hover over, link) to clinician Provide structure during handoff so consideration

9536. Shared Decision-Making About Screening and Chemoprevention: A Suggested Approach (pdf file)
      www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/sharedba.pdf
      January 01, 2004 - decisions are “likely to be sensitive to individual patient preferences.”1 Explicit language encouraging consideration … D: There is fair evidence to support the recommendation that the condition be excluded from consideration … E: There is good evidence to support the recommendation that the condition be excluded from consideration

9537. Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Update of the Evidence (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/y6xRBv7uSZY5bGCx7y48x7
      May 01, 2009 - The USPSTF developed 2 key questions (KQs) from the analytic framework to guide its consideration of … concealment and whether potential confounders were distributed equally among groups For cohort studies: Consideration … of potential confounders with either restriction or measurement for adjustment in the analysis; consideration

9538. Archived: Final Evidence Summary: Folic Acid to Prevent Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary25/folic-acid-to-prevent-neural-tube-defects-preventive-medication-2009
      May 15, 2009 - The USPSTF developed 2 key questions (KQs) from the analytic framework to guide its consideration of … concealment and whether potential confounders were distributed equally among groups For cohort studies: Consideration … of potential confounders with either restriction or measurement for adjustment in the analysis; consideration

9539. Making Healthcare Safer III: Executive Summary | Agency for Healthcare Research and Quality
      www.ahrq.gov/research/findings/making-healthcare-safer/mhs3/exe-summary.html
      March 01, 2020 - factors to delirium in a variety of care settings, and strategies to appropriately manage delirium Consideration … When using a specific PSP, consideration must be given to potential new harms that can be introduced. … It is extremely difficult, and sometimes may be impossible, to design a study that takes into consideration

9540. Vascular Access Device (VAD) Policy, Adult (pdf file)
      ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/hai/clabsi-tools/vascular-access-device-policy.pdf
      March 01, 2008 - Selects catheter and site guided by careful consideration of the patient’s medical condition, treatment